1. J Antimicrob Chemother. 2015 Jan;70(1):130-5. doi: 10.1093/jac/dku360. Epub
2014  Sep 30.

Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and 
non-B subtypes.

Fofana DB(1), Charpentier C(2), Maïga AI(3), Lambert-Niclot S(1), Sayon S(1), 
Désiré N(1), Simon A(4), Yazdanpanah Y(5), Katlama C(6), Descamps D(2), Calvez 
V(1), Marcelin AG(1), Soulié C(7).

Author information:
(1)Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis 
d'Epidémiologie et de Santé Publique, F-75013 Paris, France INSERM, UMR_S 1136, 
Institut Pierre Louis d'Epidémiologie et de Santé Publique, F-75013 Paris, 
France AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, F-75013 Paris, 
France.
(2)IAME, UMR 1137, Université Paris Diderot, Sorbonne Paris Cité, F-75018 Paris, 
France IAME, UMR 1137, INSERM, F-75018 Paris, France AP-HP, Hôpital 
Bichat-Claude Bernard, laboratoire de Virologie, F-75018 Paris, France.
(3)Unité d'Epidémiologie Moléculaire de la Résistance du VIH, SEREFO-FMOS/FAPH, 
Université des Sciences Techniques et des Technologies, Bamako, Mali Service de 
Laboratoire, CHU Gabriel Toure, Université des Sciences Techniques et des 
Technologies, Bamako, Mali.
(4)AP-HP, Hôpital Pitié-Salpêtrière, Service de médecine interne, F-75013 Paris, 
France.
(5)IAME, UMR 1137, Université Paris Diderot, Sorbonne Paris Cité, F-75018 Paris, 
France IAME, UMR 1137, INSERM, F-75018 Paris, France AP-HP, Hôpital 
Bichat-Claude Bernard, Service de maladies infectieuses, F-75018 Paris, France.
(6)Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis 
d'Epidémiologie et de Santé Publique, F-75013 Paris, France INSERM, UMR_S 1136, 
Institut Pierre Louis d'Epidémiologie et de Santé Publique, F-75013 Paris, 
France AP-HP, Hôpital Pitié-Salpêtrière, Service de maladies infectieuses, 
F-75013 Paris, France.
(7)Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis 
d'Epidémiologie et de Santé Publique, F-75013 Paris, France INSERM, UMR_S 1136, 
Institut Pierre Louis d'Epidémiologie et de Santé Publique, F-75013 Paris, 
France AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, F-75013 Paris, 
France cathia.soulie@psl.aphp.fr.

OBJECTIVES: The genetic barrier (defined as the number of genetic 
transitions/transversions needed to produce a resistance mutation) can differ 
between HIV-1 subtypes. The genetic barrier for the new attachment inhibitor 
BMS-626529 was evaluated in five HIV-1 subtypes.
METHODS: Nine substitutions associated with BMS-626529 resistance at seven amino 
acid positions (116, 204, 375, 426, 434, 475 and 506) were analysed in 300 
nucleotide sequences of the env gene encoding the gp120 protein from 
antiretroviral-naive patients (60 for each subtype and recombinant: B, C, D, 
CRF01_AE and CRF02_AG).
RESULTS: Differently from the B subtype, some resistance mutations were found as 
natural polymorphisms in the C and D subtypes and the CRF02_AG and CRF01_AE 
recombinants for four positions of the env gene encoding the gp120 protein (375, 
426, 434 and 475). The majority (five out of seven) of amino acid positions 
studied (116, 426, 434, 475 and 506) were relatively conserved (>63%) between 
the five HIV-1 subtypes, leading to a similar genetic barrier to mutations 
associated with resistance to BMS-626529. However, at positions 116 and 506 a 
minority of C and CRF02_AG subtypes had codons leading to a higher genetic 
barrier. Different predominant codons were observed at two out of seven 
positions (204 and 375) between the subtypes, with no effect on the calculated 
genetic barrier. However, for position 375, a minority of CRF02_AG sequences 
showed a lower genetic barrier to S375M/T resistance mutations.
CONCLUSIONS: In non-B HIV-1 subtypes, four out of seven studied positions 
presented mutations implicated in BMS-626529 resistance. Despite great 
variability of the HIV-1 envelope, there was no major impact of polymorphisms on 
the genetic barrier to acquisition of BMS-626529 resistance.

© The Author 2014. Published by Oxford University Press on behalf of the British 
Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, 
please e-mail: journals.permissions@oup.com.

DOI: 10.1093/jac/dku360
PMID: 25270328 [Indexed for MEDLINE]